These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 15998777)

  • 1. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
    Kahaly GJ; Pitz S; Hommel G; Dittmar M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
    Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study.
    van Geest RJ; Sasim IV; Koppeschaar HP; Kalmann R; Stravers SN; Bijlsma WR; Mourits MP
    Eur J Endocrinol; 2008 Feb; 158(2):229-37. PubMed ID: 18230831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial.
    Wakelkamp IM; Baldeschi L; Saeed P; Mourits MP; Prummel MF; Wiersinga WM
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):323-8. PubMed ID: 16117821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.
    Hart RH; Kendall-Taylor P; Crombie A; Perros P
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):328-36. PubMed ID: 16117697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
    Bartalena L
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
    Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
    Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
    Zang S; Ponto KA; Kahaly GJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):320-32. PubMed ID: 21239515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy.
    Kahaly G; Pitz S; Müller-Forell W; Hommel G
    Clin Exp Immunol; 1996 Nov; 106(2):197-202. PubMed ID: 8918563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Jpn J Ophthalmol; 2002; 46(5):563-7. PubMed ID: 12457917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.